Source-grounded facts extracted from HERON THERAPEUTICS, INC. /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HERON THERAPEUTICS, INC. /DE/ shareholders approved Ratification of adoption of Tax Benefits Preservation Plan (non-binding advisory) at the 2026-06-11 meeting.
“Proposal 6: The Company’s stockholders ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan: For Against Abstain Broker Non-Votes 88,182,895 3,442,815 186,146 50,116,083”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Approval of amendment to the 1997 Employee Stock Purchase Plan, increasing authorized shares by 10,000,000 at the 2026-06-11 meeting.
“Proposal 5: The Company’s stockholders approved the amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares: For Against Abstain Broker Non-Votes 83,765,950 6,496,205 1,549,701 50,116,083”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Approval of amendment and restatement of the 2007 Amended and Restated Equity Incentive Plan, increasing authorized shares by 16,560,000 at the 2026-06-11 meeting.
“Proposal 4: The Company’s stockholders approved the amendment and restatement of the Company’s 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares: For Against Abstain Broker Non-Votes 75,620,741 13,846,030 2,345,085 50,116,083”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Non-binding advisory vote on compensation of Named Executive Officers for fiscal year 2025 at the 2026-06-11 meeting.
“Proposal 3: The Company’s stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company’s Named Executive Officers during the fiscal year ended December 31, 2025: For Against Abstain Broker Non-Votes 77,315,474 12,117,861 2,378,521 50,116,083”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Ratification of appointment of Withum Smith+Brown, PC as independent registered public accounting firm for fiscal year 2026 at the 2026-06-11 meeting.
“Proposal 2: The Company’s stockholders ratified the appointment of Withum Smith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Votes 139,715,514 1,706,193 506,232 0”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Election of seven director nominees at the 2026-06-11 meeting.
“Proposal 1: The Company’s stockholders elected the seven director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Name of Director Nominee For Against Abstain Broker Non-Votes Mr. Collard 87,289,779 4,336,869 185,208 50,116,083 Mr. Cusack Dr. Dissanaike 88,537,725 87,960,023 3,088,305 3,729,614 185,826 122,219 50,116,083 50,116,083 Mr. Johnson 87,703,801 3,972,919 135,136 50,116,083 Mr. Kaseta 88,236,408 3,424,597 150,851 50,116,083 Mr. Morgan 88,295,437 3,381,282 135,137 50,116,083 Mr. Waage 85,276,872 6,399,195 135,789 50,116,083”
HERON THERAPEUTICS, INC. /DE/ reported the three months ended March 31, 2026 results: revenue $34.7 million. Guidance reaffirmed.
“Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million”
HERON THERAPEUTICS, INC. /DE/: Filing of Certificate of Designation of Series A Convertible Preferred Stock (effective 2025-08-11).
“the Board authorized and the Company filed, on August 11, 2025, the Certificate of Designation of Rights, Preferences and Privileges (the “Certificate of Designation’) of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Convertible Preferred Stock”), with the Secretary of State of the State of Delaware.”
HERON THERAPEUTICS, INC. /DE/ incurred convertible notes of aggregate purchase price of $35.0 million with Rubric Capital Management LP at 5% per annum interest maturing 55 months.
“On August 8, 2025, the Company, entered into a Note Purchase Agreement (the “2031 Note Purchase Agreement”) with the purchasers from time to time party thereto (collectively, the “Purchasers”) and Rubric Capital Management LP, a Delaware limited partnership (“Rubric”), as agent for the Purchasers, pursuant to which the Company will issue and sell to the Purchasers convertible senior unsecured promissory notes for an aggregate purchase price of $35.0 million pursuant to exemptions from registration under Section 4(a)(2) under the Securities Act of 1933, as amended (the “Convertible Note Issuance”).”
HERON THERAPEUTICS, INC. /DE/ incurred credit facility of up to $150.0 million with Hercules Capital, Inc. at Prime (7.5% floor) plus 1.95% cash interest and 1.00% paid-in-kind interest maturing the earlier of (i) September 1, 2030 and (ii) to the extent that the Company issues convertible indebtedness, the date 180 days prior to the stated maturity the.
“institutions or entities from time to time parties thereto. The Second Amendment amends the Loan Agreement (a) to increase the aggregate principal amount of terms loans of up to $150.0 million plus accrued and unpaid paid-in-kind interest on the existing debt, with tranched availability as follows: $110.0 million plus accrued and unpaid paid-in-kind interest on the”
Mark Hensley was appointed as Chief Operating Officer at HERON THERAPEUTICS, INC. /DE/.
“On April 28, 2025, Heron Therapeutics, Inc. (the “ Company ”) announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025”
Michael Kaseta was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
“On November 4, 2024, the Board of Directors (the "Board") of Heron Therapeutics, Inc. (the "Company") appointed Michael Kaseta to the Board to serve for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.”
HERON THERAPEUTICS, INC. /DE/ reported three months ended March 31, 2024 results: revenue Net Product Sales of $34.7 million, EPS Net Loss Per Share $(0.02). Guidance reaffirmed.
“Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.”
Lisa Peraza departed as Chief Accounting Officer at HERON THERAPEUTICS, INC. /DE/.
“Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.”
Ira Duarte changed role as principal accounting officer at HERON THERAPEUTICS, INC. /DE/.
“On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.’s principal accounting officer, replacing Lisa Peraza, the Company’s current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the “Effective Date”).”
HERON THERAPEUTICS, INC. /DE/ updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).
“On March 12, 2024, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023 (“Earnings Press Release”).”
HERON THERAPEUTICS, INC. /DE/ entered into Co-Promotion Agreement with Crosslink Network, LLC valued at Up to 1,666,670 shares of common stock; cash base compensation on fixed-fee per vial basis; up to $5 (effective 2024-01-05).
“On January 5, 2024, Heron Therapeutics, Inc. (the “Company”) and Crosslink Network, LLC (“Crosslink”) entered into a Co-Promotion Agreement (the “Co-Promotion Agreement”).”
Kevin Kotler resigned as member of the board of directors at HERON THERAPEUTICS, INC. /DE/.
“On December 20, 2023, Kevin Kotler resigned as a member of the board of directors (the “Board”) of Heron Therapeutics, Inc. (the “Company”), effective December 31, 2023.”
HERON THERAPEUTICS, INC. /DE/ updated its three and nine months ended September 30, 2023 guidance (raised).
“On November 14, 2023, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 (“Earnings Press Release”).”
HERON THERAPEUTICS, INC. /DE/ updated its the three and six months ended June 30, 2023 guidance (reaffirmed).
“On August 14, 2023, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023”
HERON THERAPEUTICS, INC. /DE/ entered into Securities Purchase Agreement with Rubric Capital Management LP, Velan Capital, Clearline Capital and Hercules Capital, Inc. valued at approximately $30.0 million (effective 2023-07-21).
“On July 21, 2023, Heron Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) for a private placement (the “ Private Placement ”) with Rubric Capital Management LP (“ Rubric ”), Velan Capital (“ Velan ”), Clearline Capital and Hercules Capital, Inc. (each a “ Purchaser ”, and collectively, the “ Purchasers ”).”
David Szekeres resigned as Executive Vice President, Chief Operating Officer at HERON THERAPEUTICS, INC. /DE/.
“On July 20, 2023, by mutual agreement, David Szekeres resigned as Executive Vice President, Chief Operating Officer of the Company, effective July 20, 2023.”
Ira Duarte was appointed as Chief Financial Officer at HERON THERAPEUTICS, INC. /DE/.
“appointed Ira Duarte as Chief Financial Officer, effective June 16, 2023”
HERON THERAPEUTICS, INC. /DE/: Amendment to Certificate of Incorporation to increase authorized shares of common stock from 150,000,000 to 225,000,000 (effective 2023-06-09).
“At the Annual Meeting, the Company’s stockholders approved and adopted an amendment to the Company’s Certificate of Incorporation, to increase the total number of shares of common stock authorized for issuance from 150,000,000 shares to 225,000,000 shares (the “ Charter Amendment ”).”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Amendment to the Company’s 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance from 1,825,000 to 2,225,000..
“Proposal 6: Amendment to the Company’s 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder from 1,825,000 to 2,225,000: For Against Abstain Broker Non-Votes 69,697,124 1,603,862 175,968 23,588,686”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Amendment to the Company’s 2007 Amended and Restated Equity Incentive Plan to increase the number of shares of common stock authorized for issuance from 30,700,000 to 39,190,000..
“Proposal 5: Amendment to the Company’s 2007 Amended and Restated Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder from 30,700,000 to 39,190,000: For Against Abstain Broker Non-Votes 56,253,856 14,934,421 288,677 23,588,686”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Amendment to the Company’s Certificate of Incorporation to increase the aggregate number of authorized shares of common stock by 75,000,000 from 150,000,000 to 225,000,000..
“Proposal 4: Amendment to the Company’s Certificate of Incorporation to increase the aggregate number of authorized shares of common stock by 75,000,000 from 150,000,000 to 225,000,000: For Against Abstain Broker Non-Votes 68,794,453 2,476,711 205,790 23,588,686”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Advisory vote to approve compensation paid to the Company’s Named Executive Officers during the year ended December 31, 2022. at the 2022-12-31 meeting.
“Proposal 3: Advisory vote to approve compensation paid to the Company’s Named Executive Officers during the year ended December 31, 2022: For Against Abstain Broker Non-Votes 69,340,148 1,730,470 406,336 23,588,686”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Ratification of the appointment of Withum Smith+Brown, PC as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-12-31 meeting.
“Proposal 2: Ratification of the appointment of Withum Smith+Brown, PC as the Company’s independent registered public accounting firm for the year ending December 31, 2023: For Against Abstain Broker Non-Votes 94,461,433 384,912 219,295 0”
HERON THERAPEUTICS, INC. /DE/ shareholders approved Election of seven director nominees to serve until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified..
“Proposal 1: Election of seven director nominees to serve until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Name of Director Nominee For Against Abstain Broker Non-Votes Adam Morgan 70,193,794 982,661 300,499 23,588,686 Craig Collard 70,704,459 680,282 92,213 23,588,686 Sharmila Dissanaike 69,647,185 1,529,163 300,606 23,588,686 Craig Johnson 69,771,541 1,405,655 299,758 23,588,686 Kevin Kotler 70,231,798 938,366 306,790 23,588,686 Susan Rodriguez 69,745,506 1,434,506 296,942 23,588,686 Christian Waage 69,684,886 1,485,469 306,599 23,588,686”
William Forbes was appointed as Executive Vice President, Chief Development Officer at HERON THERAPEUTICS, INC. /DE/.
“Additionally, effective as of June 6, 2023, William Forbes joined the Company as Executive Vice President, Chief Development Officer.”
Kimberly Manhard resigned as Executive Vice President, Drug Development at HERON THERAPEUTICS, INC. /DE/.
“Kimberly Manhard resigned as Executive Vice President, Drug Development of the Company, effective June 6, 2023.”
Jason Grillot was appointed as Vice President, Sales and Marketing, Acute Care at HERON THERAPEUTICS, INC. /DE/.
“Additionally, effective April 24, 2023, Jason Grillot will join the Company as Vice President, Sales and Marketing, Acute Care.”
Michael Mathews departed as Senior Vice President Commercial, Acute Care at HERON THERAPEUTICS, INC. /DE/.
“Also effective April 30, 2023, Michael Mathews will cease to serve as the Senior Vice President Commercial, Acute Care of the Company.”
John Poyhonen departed as President and Chief Commercial Officer at HERON THERAPEUTICS, INC. /DE/.
“Effective as of April 30, 2023, John Poyhonen will cease to serve as the President and Chief Commercial Officer of Heron Therapeutics, Inc. (the “Company”).”
Barry Quart departed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.
“Mr. Collard succeeds Barry Quart, who will cease to serve as the Company’s Chairman, Chief Executive Officer and a director as of the Effective Date”
Adam Morgan was appointed as Chairman of the Board at HERON THERAPEUTICS, INC. /DE/.
“appointed current director Adam Morgan to serve as Chairman of the Board, effective as of the Effective Date”
Craig Collard was appointed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.
“appointed Craig Collard as the Company’s Chief Executive Officer, effective April 3, 2023”
HERON THERAPEUTICS, INC. /DE/ reported full-year 2023 results: revenue $99 million to $103 million. Guidance initiated.
“Heron currently expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.”
HERON THERAPEUTICS, INC. /DE/ reported the three and twelve months ended December 31, 2022 results: revenue $30.0 million and $107.7 million, net income $19.9 million, or $0.17 per share, and $182.0 million, or $1.67 per share, EPS $0.17 per share and $1.67 per share.
“Net product sales for the three and twelve months ended December 31, 2022 were $30.0 million and $107.7 million, respectively, compared to $20.7 million and $86.3 million, respectively, for the same periods in 2021.”
HERON THERAPEUTICS, INC. /DE/ entered into Cooperation Agreement with Rubric Capital Management LP, Velan Capital Investment Management LP, and the persons and entities listed on Schedules A and B thereto (effective 2023-02-21).
“On February 21, 2023, Heron Therapeutics, Inc. (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) with Rubric Capital Management LP and the persons and entities listed on Schedule A thereto (collectively, “Rubric”), Velan Capital Investment Management LP and the persons and entities listed on Schedule B thereto (collectively, “Velan” and, together with Rubric, the “Investor Group”) regarding certain changes to the composition of the Company’s Board of Directors (the “Board”) and other related matters.”
Kimberly Manhard resigned as Director at HERON THERAPEUTICS, INC. /DE/.
“Directors Stephen Davis and Kimberly Manhard resigned as members of the Board effective February 21, 2023.”
Stephen Davis resigned as Director at HERON THERAPEUTICS, INC. /DE/.
“Directors Stephen Davis and Kimberly Manhard resigned as members of the Board effective February 21, 2023.”
Kevin Kotler was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
“the Board increased the size of the Board from seven to eight directors and appointed Adam Morgan, Craig Collard, and Kevin Kotler to the Board.”
Craig Collard was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
“the Board increased the size of the Board from seven to eight directors and appointed Adam Morgan, Craig Collard, and Kevin Kotler to the Board.”
Adam Morgan was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
“the Board increased the size of the Board from seven to eight directors and appointed Adam Morgan, Craig Collard, and Kevin Kotler to the Board.”
HERON THERAPEUTICS, INC. /DE/ reported Three and twelve months ended December 31, 2022 results: revenue The company issued a press release announcing certain of its preliminary financial results for the three and twelve mont.
“On January 9, 2023, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain of its preliminary financial results for the three and twelve months ended December 31, 2022 (the “Press Release”).”
HERON THERAPEUTICS, INC. /DE/ reported three and nine months ended September 30, 2022 results: revenue $26.6 million and $77.6 million, net income $41.9 million, or $0.38 per share, and $162.2 million, or $1.54 per share. Guidance reaffirmed.
“franchises and extend our runway against a challenging external backdrop.” Financial Results Net product sales for the three and nine months ended September 30, 2022 were $26.6 million and $77.6 million, respectively, compared to $23.2 million and $65.7 million, respectively, for the same periods in 2021. Heron’s net loss for the three and nine months ended”
Susan Rodriguez was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
“Effective as of September 20, 2021, the Board appointed Susan Rodriguez to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.”
Sharmila Dissanaike was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
“Effective as of September 20, 2021, the Board of Directors (the “Board”) of Heron Therapeutics, Inc. (the “Company”) appointed Sharmila Dissanaike, M.D. to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.